Table 1. Statistics of in vivo tumor experiments.
| Days after | Average | p-value | TFS during treatment | Median | p-value | TFS >100 days | |||
| Exp. | Treatment | # mice | Inoculation1 | tumor size (mm2) | tumor size* | (# mice) | survival | survival** | (# mice) |
| (+/− SEM) | (vs. untreated) | (% of group) | (days) | (% of group) | |||||
| 1 | untreated | 7 | 22 | 64.8 (14.3) | nt | 0 | nt | nt | nt |
| monobenzone | 7 | 22 | 27.1 (7.5) | <0.04 | 0 | nt | nt | nt | |
| MIC | 7 | 22 | 3.1 (1.9) | <0.0011 | 4 (57%) | nt | nt | nt | |
| 2 | untreated | 5 | 18 | 70.6 (18.0) | nt | 0 | nt | nt | nt |
| monobenzone | 5 | 18 | 50.0 (29.7) | ns | 0 | nt | nt | nt | |
| CpG | 5 | 18 | 14.4 (3.5) | <0.02 | 0 | nt | nt | nt | |
| imiquimod | 5 | 18 | 61.6 (7.2) | ns | 0 | nt | nt | nt | |
| CI | 5 | 18 | 9.0 (4.5) | <0.02 | 0 | nt | nt | nt | |
| MIC | 5 | 18 | 5.6 (3.0) | <0.008 | 2 (40%) | nt | nt | nt | |
| 3 | untreated | 11 | 27 | 81.6 (20.2) | nt | 0 | 40 | nt | 0 |
| MIC | 11 | 27 | 0.4 (0.2) | <0.0006 | 8 (72%) | >100 | <0.0001 | 7 (64%) | |
| 4 | untreated | 7 | 27 | 187.9 (13.4) | nt | 0 | 27 | nt | 0 |
| monobenzone | 7 | 27 | 88.9 (35.3) | <0.03 | 1 (14%) | 34 | <0.03 | 1 (14%) | |
| CpG | 7 | 27 | 71.1 (30.0) | <0.004 | 0 | 35 | <0.005 | 0 | |
| imiquimod | 7 | 27 | 102.9 (31.9) | <0.04 | 0 | 34 | <0.03 | 0 | |
| CI | 7 | 27 | 13.0 (5.3) | <0.0001 | 1 (14%) | 36 | <0.0003 | 1 (14%) | |
| MIC | 7 | 27 | 6.0 (6.0) | <0.0001 | 6 (85%) | >200 | <0.0003 | 4 (57%) |
ns: not significant (considered if p>0.05). Exp.: experiment.
nt: not tested. TFS: tumor-free survival.
*: Unpaired t-test. CI: CpG & imiquimod.
**: Logrank test for survival (endpoint tumor size max 200 mm2). MIC: monobenzone, imiquimod & CpG.
1
:Day of tumor size comparison (last day on which experimental animals were all alive).
For Exp. 2 see Fig. 1A/B, for Exp. 3 see Fig. 3C (upper panel), for Exp. 4 see Fig. 3A/B and C (lower panel),